Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Sulfonamide fibrinogen receptor antagonists|
|Abstract:||A series of non-peptide derivatives that are antagonists of the fibrinogen IIb/IIIa receptor and thus are platelet anti-aggregation compounds useful in the prevention and treatment of diseases caused by thrombus formation.|
|Inventor(s):||Duggan; Mark E. (Narberth, PA), Halczenko; Wasyl (Hatfield, PA), Egbertson; Melissa S. (Ambler, PA), Hartman; George D. (Lansdale, PA), Laswell; William L. (Perkasie, PA)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
|Filing Date:||Dec 28, 1998|
|Claims:||1. A method for treating thrombus formation in a mammal in need thereof, comprising administering an effective amount of a compound of the structural formula ##STR209## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl, wherein aryl is phenyl, pyridyl, thienyl, tetrazole or oxazole; ##STR210## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR211## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl; |
Z is ##STR212## p is zero or one; and m is an integer from two to six, in combination with an effective amount of fibrinolytic agent.
2. A method of claim 1, wherein the compound has the structural formula ##STR213## or a pharmaceutically acceptable salt thereof, wherein R.sup.4 is aryl, C.sub.1-10 alkyl, or C.sub.4-10 aralkyl, wherein aryl is phenyl, pyridyl, thiophenyl, tetrazole, or oxazole;
R.sup.5 is ##STR214## wherein R.sup.8 is hydroxy or C.sub.1-10 alkyloxy, ##STR215## wherein R.sup.9 and R.sup.10 are selected from the group consisting of hydrogen, C.sub.1-10 alkyl and phenyl C.sub.1-4 alkyl;
Z is O;
p is zero or one; and m is an integer from two to six and the fibrinolytic agent is selected from the group consisting of streptokinase and tissue plasminogen activator.
3. A method of claim 2, wherein the compound is ##STR216## or a pharmaceutically acceptable salt thereof, and the fibrinolytic agent is tissue plasminogen activator.
4. The method of claim 3, wherein the salt is ##STR217##
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.